Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

821.51 -3.94 (-0.48%)
Streaming Delayed Price Updated: 1:41 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Mounjaro Maker Eli Lilly Clocks 45% Jump In Q1 Revenue, Cuts 2025 Profit Outlook But Not Due To Tariffs
Eli Lilly cut its 2025 profit outlook after strong Q1 sales from Mounjaro and Zepbound and a $1.57 billion charge tied to a cancer drug acquisition. 
Via Benzinga
Eli Lilly Stock Falls After Zepbound Sales Miss, Full-Year Profit Outlook Cut
The company cut its adjusted earnings per share guidance for the full year to $22.50 to $24.00, down from its previous forecast of $20.78 to $22.28. 
Via Stocktwits
Topics Earnings Government
Eli Lilly Slumps 5% On Profit Guidance Cut Despite Mounjaro, Zepbound Beats
The drugmaker cut its profit guidance for the year, but kept its sales outlook. 
Via Investor's Business Daily
Beat the Nasdaq With This Cash-Gushing Dividend Stock
Via The Motley Fool
Topics Economy Stocks
If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year? 
Via Investor's Business Daily
Topics Animal Testing Economy Government
Earnings Scheduled For May 1, 2025
 
Via Benzinga
Price Over Earnings Overview: Eli Lilly
 
Via Benzinga
Eli Lilly (NYSE:LLY) Beats Q1 Sales Targets
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 45.2% year on year to $12.73 billion. The company expects the... 
Via StockStory
US Stock Futures Rise As Meta, Microsoft Earnings Fuel Optimism: GDP Slump Linked To Tariff Anticipation, Not Recession, Says Analyst
U.S. stock futures rose early Thursday morning, following the robust earnings of two "Mag 7" companies after markets closed on Wednesday. 
Via Benzinga
Topics Economy
1 Beaten-Down Stock to Buy and Hold for 10 Years
Via The Motley Fool
Topics Economy
Where Is Hims & Hers Stock Headed After Wegovy Tie-Up? Retail Traders Bet On Rebound To Over 2-Month High
Needham called the tie-up a “groundbreaking partnership” and said it alleviates investor concerns around Hims’ ability to hit its 2025 weight loss revenue guidance. 
Via Stocktwits
Eli Lilly Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
 
Via Benzinga
Nasdaq, Dow Jones Futures Rise On Meta, Microsoft Results: Apple Earnings Loom, Analyst Doubts New Bull Run For Stock Markets
Notwithstanding the recent seven-session run, the S&P 500 Index ended April — a historically strong month — with a loss of 0.8%. 
Via Stocktwits
Topics Economy Stocks World Trade
New Weight Loss Pill & Massive U.S. Investment Sends Eli Lilly Stock Soaring – Is It Too Late To Buy?
Eli Lilly, a pharmaceutical leader in obesity and diabetes treatment, is back in the spotlight, and for good reason. 
Via Talk Markets
Eli Lilly Stock Has The Technicals: Will Q1 Earnings Deliver Fundamentals?
Eli Lilly reports 1Q earnings on Thursday, with EPS of $3.05 and revenues of $12.67 billion expected. Stock is up 14.35% in past year. 
Via Benzinga
Market Whales and Their Recent Bets on LLY Options
 
Via Benzinga
Eli Lilly's Stock Is Up 15% This Year, and Here's Why It Could Take Off Even More
Via The Motley Fool
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
Via The Motley Fool
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain
Via The Motley Fool
What To Expect From Eli Lilly’s (LLY) Q1 Earnings
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow before market hours. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
WeightWatchers Stock Rockets After Partnership For Eli Lilly's Zepbound Drug: Retail Investors Very Optimistic
Eligible self-pay patients without insurance can now access prescriptions for Zepbound in single-dose vial form through the WeightWatchers app. 
Via Stocktwits
Topics Bankruptcy
Why Is WeightWatchers (WW) Stock Soaring Today
Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 132% in the afternoon session after the company announced plans to make it easier for its members to access Eli Lilly's... 
Via StockStory
Topics Artificial Intelligence
Eli Lilly Set To Report Earnings As Investors Eye Weight Loss Drug Momentum
Eli Lilly (LLY) will report Q1 results on Thursday. Analysts expect in line results with focus on tirizepatide and obesity franchise. 
Via Benzinga
Why Viking Therapeutics Stock Popped Again Today
Cantor Fitzgerald thinks the GLP-1 diet drug VK2735 will be a "multi-blockbuster" for Viking stock. 
Via The Motley Fool
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
Hims & Hers partners with Novo Nordisk to offer Wegovy access online with clinical support, expanding its weight loss care and revenue strategy. 
Via Benzinga
WeightWatchers Integrates With Eli Lilly To Expand Access To Zepbound, Stock Skyrockets 110%
WW International shares are trading higher by 79% during Tuesday's session. The company announced a new partnership with Eli Lilly's LillyDirect pharmacy provider. 
Via Benzinga
The S&P 500 Is Doing Something That Hasn't Been Seen in Nearly 100 Years. Here Are the 10 Most Important Stocks to Keep an Eye On.
Concentration levels in the S&P 500 are at their highest levels since 1932. 
Via The Motley Fool
Topics Artificial Intelligence Stocks
WeightWatchers Bankruptcy Buzz Could Be A Strategy To 'Get A Better Deal With The Bonds,' Says Activist Investor
Galloway Capital, which owns a 2.87% stake, says WeightWatchers should avoid bankruptcy. 
Via Stocktwits
Topics Bankruptcy
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
Why AbbVie Stock Trounced the Market Today
Via The Motley Fool
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.